Corneal Endothelial Dystrophy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen

Corneal Endothelial Dystrophy Pipeline constitutes 4+ key companies continuously working towards developing 4+ Corneal Endothelial Dystrophy treatment therapies, analyzes DelveInsight.

Corneal Endothelial Dystrophy Overview:

"Corneal Endothelial Dystrophy" describes a group of disorders marked by the slow, progressive degeneration of the corneal endothelium, often linked to genetic factors. This group includes congenital hereditary endothelial dystrophy types 1 and 2 (CHED1 and CHED2), posterior polymorphous corneal dystrophy (PPCD), and Fuchs endothelial corneal dystrophy (FECD). In all forms, endothelial damage eventually causes severe vision loss or blindness, although the exact molecular mechanisms are still not fully understood. Recent research has begun to clarify these mechanisms and supports the concept of a continuum among endothelial dystrophies. FECD is the most prevalent type, characterized by the loss of endothelial cells and the development of excrescences on Descemet's membrane, often leading to significant vision impairment.

Download our report @ https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Corneal Endothelial Dystrophy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Corneal Endothelial Dystrophy Therapeutics Market.

Key Takeaways from the Corneal Endothelial Dystrophy Pipeline Report

DelveInsight's Corneal Endothelial Dystrophy pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Corneal Endothelial Dystrophy treatment.
Design Therapeutics is developing DT-168, a GeneTACTM small molecule eye drop designed to target the CTG repeat expansion in the TCF4 gene, a known cause of FECD. As of April 2025, the company has completed Phase 1 trials in healthy volunteers and plans to initiate Phase 2 trials in FECD patients. ​
In June 2024, Aurion Biotech's AURN001 received both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA. AURN001 is an allogeneic cell therapy combining neltependocel (cultured human corneal endothelial cells) with the ROCK inhibitor Y-27632, aiming to treat corneal edema resulting from endothelial dysfunction. This therapy offers a less invasive alternative to traditional corneal transplants. Aurion has completed enrollment in its Phase 1/2 CLARA trial across the U.S. and Canada. ​
In March 2023, Japan's Pharmaceuticals and Medical Devices Agency approved this therapy (marketed as Vyznova), marking the first approval of an allogeneic cell therapy for corneal endothelial disease.
Key Corneal Endothelial Dystrophy companies such as Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen, and others are evaluating new drugs for Corneal Endothelial Dystrophy to improve the treatment landscape.
Promising Corneal Endothelial Dystrophy therapies include TTHX1114, Netarsudil mesylate, and others.

Corneal Endothelial Dystrophy Pipeline Analysis
The Corneal Endothelial Dystrophy pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Corneal Endothelial Dystrophy Market.

Categorizes Corneal Endothelial Dystrophy therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Corneal Endothelial Dystrophy drugs under development based on:

Stage of development

Corneal Endothelial Dystrophy Route of administration

Target receptor

Monotherapy vs. combination therapy

Corneal Endothelial Dystrophy Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Corneal Endothelial Dystrophy Licensing agreements

Funding and investment activities supporting future Corneal Endothelial Dystrophy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Corneal Endothelial Dystrophy Emerging Drugs

TTHX1114: Trefoil Therapeutics

TTHX1114 is a proprietary, engineered version of Fibroblast Growth Factor-1 (FGF-1), a molecule that naturally promotes cell growth, migration, and protection against stress and injury. It has been modified to extend FGF-1's pharmacodynamic half-life, making it suitable for pharmaceutical use. Preclinical studies have shown that TTHX1114 stimulates endothelial cell proliferation and migration, aiding in the regeneration of the corneal endothelial layer. It is currently in Phase II development for the treatment of Corneal Endothelial Dystrophy.

Netarsudil mesylate: Aerie Pharmaceuticals

Netarsudil mesylate ophthalmic solution, developed by Aerie Pharmaceuticals through a license from Duke University Medical Center, is designed to lower intraocular pressure in cases of open-angle glaucoma and ocular hypertension, as well as to reduce or treat corneal edema associated with Fuchs' endothelial dystrophy.

Corneal Endothelial Dystrophy Companies

There are about four or more major companies working on therapies for Corneal Endothelial Dystrophy, with Trefoil Therapeutics leading the way with a drug candidate currently in Phase II development.

DelveInsight's report covers around 4+ products under different phases of Corneal Endothelial Dystrophy clinical trials like

Corneal Endothelial Dystrophy Late stage Therapies (Phase III)
Corneal Endothelial Dystrophy Mid-stage Therapies (Phase II)
Corneal Endothelial Dystrophy Early-stage Therapies (Phase I)
Corneal Endothelial Dystrophy Pre-clinical and Corneal Endothelial Dystrophy Discovery stage Therapies
Corneal Endothelial Dystrophy Discontinued & Inactive Therapies

Corneal Endothelial Dystrophy pipeline report provides the Corneal Endothelial Dystrophy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Corneal Endothelial Dystrophy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Corneal Endothelial Dystrophy Therapies and Key Corneal Endothelial Dystrophy Companies: Corneal Endothelial Dystrophy Clinical Trials and recent advancements https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Corneal Endothelial Dystrophy Pipeline Therapeutic Assessment
• Corneal Endothelial Dystrophy Assessment by Product Type
• Corneal Endothelial Dystrophy By Stage
• Corneal Endothelial Dystrophy Assessment by Route of Administration
• Corneal Endothelial Dystrophy Assessment by Molecule Type

Download Corneal Endothelial Dystrophy Sample report to know in detail about the Corneal Endothelial Dystrophy treatment market @ Corneal Endothelial Dystrophy Therapeutic Assessment https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Corneal Endothelial Dystrophy Current Treatment Patterns
4. Corneal Endothelial Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Corneal Endothelial Dystrophy Late-Stage Products (Phase-III)
7. Corneal Endothelial Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Corneal Endothelial Dystrophy Discontinued Products
13. Corneal Endothelial Dystrophy Product Profiles
14. Corneal Endothelial Dystrophy Key Companies
15. Corneal Endothelial Dystrophy Key Products
16. Dormant and Discontinued Products
17. Corneal Endothelial Dystrophy Unmet Needs
18. Corneal Endothelial Dystrophy Future Perspectives
19. Corneal Endothelial Dystrophy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Corneal Endothelial Dystrophy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.